ClinicalTrials.gg
CompletedNCT00128739Updated Aug 29, 2005

Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation

A Phase 3 interventional study of Budesonide in Graft Vs Host Disease, sponsored by Rafa Laboratories. Completed at 1 site in Israel. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2005-08-29.

Sponsored by Rafa Laboratories · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 33 studies in Graft vs Host Disease with a site in Israel — 2 open to participants now, 3 under way, none of them phase 3. Graft vs Host Disease · Israel.

Enrollment
20th of 29
24 · median 30
Started
2001
the only one that year
Phase 3
10 of 33
none open now
Registered
1st of 33
by date

Among the 33 studies in Graft vs Host Disease with a site in Israel, this one is the 20th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2001, is one of 10 in phase 3, and was the 1st registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 148 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

2 of the 33 studies in Graft vs Host Disease with a site in Israel are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 102 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 41 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Graft vs Host Disease with a site in Israel, or all of them as a file.
02

Study summary

Twenty-four (2 x 12) patients with intestinal graft versus host disease (GVHD) Grades 2, 3 or 4 will be treated with budesonide 3mg three times daily or placebo for 12 weeks. All of the patients will receive cyclosporine and by mouth (po) prednisone or intravenous (IV) methylprednisone with a starting dose of 2mg/kg/day (standard anti-GVHD treatment). Doses of steroids will be decreased by approximately 10% or 10mg per week (depending upon patient's weight) upon response to therapy, defined as a decrease of volume of diarrhea by 50% per day, decrease in abdominal pain and no presence of bloody stool. Patients with Grades 3 or 4 will be withdrawn from the study if there is no response after one week of therapy. Patients with Grade 2 may continue with no decrease in prednisone dose until response is achieved.

Read the detailed description

Graft versus host disease (GVHD) is one of the most common complications of bone marrow transplantation (BMT). Targets of GVHD are the gastro-intestinal tract (GIT) liver and skin, causing severe diarrhea and mucosal aberration and hepatitis that can cause life threatening liver failure. As a result of the mucosal aberration and the general immuno-suppression, caused both by the GVHD process itself and by the anti GVHD therapy, these patients are highly susceptible for severe, life threatening infections that usually originate from the GIT. Systemic steroids are the backbone of anti GVHD therapy. However, in GVHD systemic steroids have to be administered for a prolonged duration and in high doses, thus causing prolonged immune suppression, and exposing the patients to steroid side effects such as hypertension, diabetes, cataract formation etc.

Budesonide is a steroid that combines topical anti-inflammatory activity with high first-pass hepatic extraction. It was shown to be effective in treatment of inflammatory bowel disease with results slightly less then systemic steroids and fewer steroid-related adverse reactions. Except for its influence on the gut, budesonide was also shown to benefit inflammatory hepatic conditions such as primary biliary cirrhosis, liver transplantation and autoimmune hepatitis. Recently, it has been shown that budesonide is an effective treatment in acute GIT GVHD. The investigators propose to evaluate the effect of budesonide in GIT and hepatic GVHD with the following study.

Patients:

Twelve patients after allogenic peripheral blood stem cell transplantation (PBSCT) with grade >= 2 GIT and/or hepatic GVHD will be prospectively compared to 12 placebo controls.

Inclusion Criteria:

  • Clinical and biopsy proven grade >/= 2 GIT AND/OR hepatic GVHD.

Exclusion Criteria:

  • Preventive antimicrobial treatment (with the exception of Resprim) or somatostatin in the GIT GVHD patients.
  • Anti-GVHD treatment other then steroids (maximal dose ≤ 2 mg/kg methylprednisolone) and cyclosporine A or tacrolimus.

Study Protocol:

All patients will be assessed for GVHD scoring (organ and general) according to standard criteria and tested before inclusion for the following parameters -

  • Colon and/or liver biopsy GVHD staging (including number of crypt abscesses).
  • Liver function tests - blood albumin, AST, ALT, GGTP, Alk Phos, LDH, bilirubin, coagulation function, cholesterol.
  • Stool - volume and frequency.
  • Radiological - CT scan for mucosal edema, wall thickening and ascites.
  • Kidney function tests - blood creatinine, creatinine clearance.
  • Blood pressure.
  • Fasting blood glucose. If normal - oral glucose tolerance test, glycosylated hemoglobin.
  • Ophthalmologist evaluation for cataract formation and IOP.
  • GIT absorption assessment - xylose absorption.
  • Microbiological - stool culture and stool for CDT, CMV PCR, culture for CMV in blood and urine.
  • Bone density - by ultrasound.

After inclusion the patients will be treated with budesonide 9 or 15mg per day in divided doses or placebo. Other anti-GVHD treatment or ursodeoxycholic acid will not be withheld but tapering off will be tried.

Study parameters:

  • LFT, albumin, PT, cholesterol, renal function, stool volume and frequency, CMV culture and PCR, clinical GVHD staging - every 2 weeks.
  • Xylose test - every month.
  • Ophthalmologist evaluation, diabetes control and CT scan - every 3 months.
  • GIT and/or liver biopsy for GVHD staging (including number of crypt abscesses) and CMV PCR, bone density - every 6 months
  • Blood, urine and stool culture during every febrile episode.

Study duration: 14 weeks.

End points:

  • Hospitalizations: due to GVHD and/or due to infections.
  • Overall and GIT or hepatic GVHD staging.
  • Time to response.
  • Maximal daily diarrhea (volume and frequency).
  • Weight.
  • Liver function tests.
  • Cataract formation and IOP.
  • TNF level.
  • Albumin.
  • TPN consumption.
  • Bone density.
  • Hypertension.
  • Diabetes - presence and control.
  • Febrile episodes.
  • Positive cultures.
  • Days of antibiotic therapy.
  • Survival.
03

Conditions studied

  • Graft Vs Host Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with clinical and proven Grades 2, 3 or 4 intestinal
  • Patients with a negative stool culture
  • Male or female patients aged between 18 - 70 years
  • Signed written of the patient

Exclusion criteria

Exclusion Criteria:

  • Uncertain diagnosis (other causes of intestinal disease are possible)
  • Severe other disease which may influence the patient prognosis
  • to the use of
  • Patient's inability to swallow the study medications
  • Concurrent use of non-steroidal anti-inflammatory drug (NSAID)
  • Known spontaneous or iatrogenic disturbances of aggregation or blood clotting.
  • Kidney dysfunction with creatinine level higher than 2mg/dl
  • Patients on preventative antimicrobial therapy with the exception of Resprim® (sulfamethoxazole and trimethoprim)
  • Patients taking somatostatin
  • Patients taking anti-GVHD medication with the exception of steroids (maximum dose of prednisone or methylprednisolone 2mg/kg/day) and cyclosporine A or tacrolimus
  • Pregnancy or lactation
  • Insufficient protection
  • Participation in another clinical study within the last 30 days.
  • Mental condition rendering the patient unable to understand the nature or scope and possible consequences of the study and/or evidence of an uncooperative attitude.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
24 participants

Interventions

06

Study locations

1 site
  • Hadassah Medical Organization,
    Jerusalem, 91120, Israel
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2001 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2005
First posted
Aug 10, 2005
Start
Jan 2001
Completion
Aug 2005
Last update
Aug 29, 2005
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Aug 29, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00128739
Lead sponsor
Rafa Laboratories
First posted
Aug 10, 2005
Start date
Jan 2001
Completion
Aug 2005
Last update
Aug 29, 2005

Study contacts

Michael Y Shapira, MD
principal investigator · Hadassah Medical Organization
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion